SCHEMBL5208087

SCHEMBL5208087

COCC(=O)c1ccc(NC(C)=O)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 3/20 0.50
POLB P06746 2/20 0.49
MAPK1 P28482 2/20 0.48
NPC1 O15118 3/20 0.47
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
ALOX15 P16050 1/20 0.46
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.45
HSD17B10 Q99714 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
KMT2A Q03164 1/20 0.44
RORC P51449 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2492405 0.85 TDP1 (0.55) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL10757306 0.85 TDP1 (0.55) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL1493992 0.83 MAPK1 (0.57) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL1162352 0.81 TDP1 (0.56) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL2555975 0.81 TDP1 (0.73) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL12970763 0.80 TDP1 (0.55) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL14421098 0.80 TDP1 (0.55) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL27831799 0.79 HPGD (0.53) SMN1; SMN2ALDH1A1MAPK1HTTMAPT
SCHEMBL721054 0.79 MAPK1 (0.57) TDP1SMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL13697401 0.78 TDP1 (0.52) TDP1SMN1; SMN2ALDH1A1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 TDP1 4369/4885SMN1; SMN2 3531/4885ALDH1A1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.